

Supplementary Figures

Title: “Pyrazolopyrimidinones, a novel class of copper-dependent bactericidal antibiotics against multi-drug resistant *S. aureus*”

Authors: Cameron L. Crawford¹, Alex G. Dalecki¹, Whitney T. Narmore¹, Jessica Hoff¹, Audra A. Hargett², Matthew B. Renfrow², Man Zhang³, Madumali Kalubowilage³, Stefan H. Bossmann³, Stacy L. Queern^{4,5}, Suzanne E. Lapi^{4,5}, Robert N. Hunter III⁶, Donghui Bao⁶, Corinne E. Augelli-Szafran⁶, Olaf Kutsch¹, and Frank Wolschendorf^{1,#}

¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

²Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, USA

³ Department of Chemistry, Kansas State University, Manhattan, KS, USA

⁴ Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA

⁵ Department of Chemistry, Washington University in St. Louis

⁶ Department of Chemistry, Drug Discovery Division, Southern Research, Birmingham, AL, USA

A

csoR-binding motif

WT aacgcaacgattgacttatatacctatagg**g**ggtacattagacgtgtaa
MNG3 aacgcaacgattgacttatatacctatagg**t**ggtacattagacgtgtaa






Figure S1: Changes in sensitivity of $\Delta copA$ and MNG3 to Cu. **a)** Alignment of the predicted *copA* promoter region of WT *S. aureus* strain Newman to that of the Cu resistant mutant, MNG3. The promoter was predicted using the PromoterHunter online software. The G to T mutation within the binding site of the copper-sensitive transcriptional repressor CsoR is shown in red. The last base pair shown is 25 bp upstream of the *copA* start site. **b)** A *copA* KO strain was tested for sensitivity to Cu. **c)** Expression of *copA* in WT *S. aureus* strain Newman (black) and MNG3 (gray) with and without 30 mins of Cu exposure. Data are expressed as fold change to WT in the absence of Cu. **d)** MNG3 was tested for sensitivity to Cu.




Figure S2: Calibration curve of pH responsive GFP. A series of phosphate-citrate buffers (pH 5.0 to 8.5) containing the lysate of *S. aureus* cells expressing the pH sensitive GFP were read. Error bars represent the coefficient of variation for the ratios.




Figure S3: Copper-dependency of 915's anti-staphylococcal activity. Impact of BCS (500 μM) on 915's inhibitory qualities against *S. aureus* Newman in the presence and absence of copper sulfate (50 μM).




Figure S4: Determination of metal binding by 915 using UV/VIS. a) UV/Vis spectrum of 915, 915+CuBr₂, 915+ZnSO₄, 915+FeCl₂, and CuBr₂ in 25μM HEPES buffer (pH=7.2). a) 1.54×10^{-5} M CuBr₂, b) 8.58×10^{-4} M PZP-915, c) 1.54×10^{-5} M CuBr₂ + 2.14×10^{-4} M PZP-915, d) 1.54×10^{-5} M FeCl₂ + 2.14×10^{-4} M PZP-915, e) 1.54×10^{-5} M ZnSO₄ + 2.14×10^{-4} M PZP-915. Typical absorption maxima were discerned at the following wavelength: PZP-915: 320 nm, PZP-915 + CuBr₂: 285nm and 315 nm, PZP-915 + FeCl₂: 282nm and 315nm (shoulder), PZP-915 + ZnSO₄: 282nm and 315nm (shoulder) b) Job plot of Fe(II), Cu(II), and Zn(II) with 915 at absorbance maximums. All three complexes have $M(\text{PZP915})_3^{2+}$ stoichiometry




Figure S5: Toxicity of Fe and Zn on *S. aureus*. Sensitivity of *S. aureus* to FeCl_3 and ZnCl_2 .




Figure S6: Killing by 915+Cu requires low micromolar amounts of copper. *S. aureus* Newman was treated with indicated concentrations of CuSO₄ and PZP 915 in standard assay medium. At the indicated times, 5 μl of the treated culture were removed and spotted for recovery onto MH-agar pates. Images were taken after overnight incubation at 37°C.




Figure S7: Longer treatment with 915 does not drastically increase membrane permeability. Membrane integrity was monitored using the membrane impermeable fluorescent indicator probe TO-PRO-3. Heat killed *S. aureus* cells served as positive control. A small number of live cells were added prior staining for control purposes. At the time when TO-PRO-3 fluorescence was taken, cells were exposed to Cu, 915 or 915+Cu for 8h. Treatments were 10 μ M 915 + 50 μ M Cu (blue), 10 μ M 915 (green), 50 μ M Cu (yellow), untreated (orange), and Heat-killed (HK, grey). Membrane integrity staining after a 30 min treatment is shown in Fig. 4B.




Figure S8: *S. aureus* metallomics response to 915 treatment. **a)** Fold-change of the metal content of *S. aureus* treated with 50 μ M Cu (black), 10 μ M 915 (blue), or 10 μ M 915 + 50 μ M Cu (pink) are shown. Fold change was calculated as a ratio of the amount of the indicated metal for the experimental value and untreated value. Dotted lines represent a +2 fold-change or -2 fold-change. Error bars represent the coefficient of variation. **b)** Percent difference of total cations measured in comparison to the control. 50 μ M Cu (black), 10 μ M 915 (light grey) 10 μ M 915 + 50 μ M Cu (dark grey). Error bars represent the variance. **c)** The amounts of each cation measured are stacked to represent the change in each metal after treatment. Cu (black), K (blue), Na (grey), Zn (dark pink), Fe (orange), Mn (purple), Ca (light pink), and Mg (green). Error bars represent standard deviation. Mn levels for the 915 and 915 + Cu treatments reached below the limit of detection, and so the bars represent the limit of detection.




Figure S9: Recovery of *S. aureus* copper-treated cells on MH-agar. *S. aureus* Newman was treated with indicated concentrations of CuSO_4 in standard assay medium. At the indicated times, 5 μl of the treated culture were removed and spotted for recovery onto MH-agar pates. Images were taken after overnight incubation at 37°C .




Figure S10: PZP 915 synthesis. Synthesis of 5-benzyl-3-(4-chlorophenyl)-2-methyl-4H,7H-pyrazolo[1,5-a]pyrimidin-7-one in three linear steps.




Figure S11: PZP 915 confirmation by ¹H-NMR. ¹H-NMR Spectrum of 5-benzyl-3-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]pyrimidin-7(4H)-one (**4**).




Figure S12: PZP 915 confirmation by ¹³C-NMR. ¹³C-NMR Spectrum of 5-benzyl-3-(4-chlorophenyl)-2-methylpyrazolo[1,5-a] pyrimidin-7(4H)-one (**4**).